Tumor targeted gene therapy with plasmid expressing human tumor necrosis factor alpha in vitro and in vivo.
We have assessed the effect of exogenous human tumor necrosis factor alpha (hTNFalpha) in three human cancer cell lines; MDA-MB-361 (breast adenocarcinoma), HCT 116 (colon carcinoma) and 8-MG-BA (glioma). In vitro transfection of a plasmid containing hTNFalpha under the control of a hybrid promoter resulted in expression of hTNFalpha gene in all three cell lines and secretion into the culture medium was seen with MDA-MB-361 cells. Flow cytometric analysis showed a significant increase in apoptotic and necrotic cells in MDA-MB-361 and to a lesser extent in HCT 116 cells. Increased apoptosis was confirmed by an increase in pro-caspase 3 activation. No effects of hTNFalpha expression were seen in 8-MG-BA cells. Intratumoral delivery of the hTNFalpha expression plasmid into MDA-MB-361 tumor xenografts grown in nude mice caused hemorrhagic tumor necrosis. This strategy may be a simple and promising gene therapy approach to the treatment of some human tumors.
Pastorakova
A
A
Cancer Research Institute, Slovak Academy of Sciences, 833 91 Bratislava, Slovak Republic. exonada@savba.sk
Hlubinova
K
K
Bodo
J
J
Libby
J
J
Rychly
B
B
Margison
G
G
Altaner
C
C
D000230:Adenocarcinoma / Q000235:genetics* / Q000473:pathology; D017209:Apoptosis; D001932:Brain Neoplasms / Q000235:genetics* / Q000473:pathology; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology; D002277:Carcinoma / Q000235:genetics* / Q000473:pathology; D003110:Colonic Neoplasms / Q000235:genetics* / Q000473:pathology; D005260:Female; D005434:Flow Cytometry; D015316:Genetic Therapy; D005910:Glioma / Q000235:genetics* / Q000473:pathology; D006801:Humans; D009336:Necrosis; D010957:Plasmids; D011401:Promoter Regions, Genetic; D019076:Transgenes; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics* / Q000502:physiology
D014409:Tumor Necrosis Factor-alpha